GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported initial efficacy and safety results at 4 yearsa post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ® (GS010; lenadogene nolparvovec). The results show that four years afte